spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  hydrocortisone 

 HSMN NewsFeed - 17 Aug 2015
European Commission Grants Marketing Authorisation for Unituxin(TM) (dinutuximab) for the Treatment of Paediatric High-Risk Neuroblastoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Jul 2014
Salix and Pharming Announce FDA Approval of RUCONEST(R) for the Treatment of Acute Angioedema Attacks in Patients with Hereditary Angioedema (HAE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Nov 2013
Shire to Acquire ViroPharma in Strategic Move to Strengthen Rare Disease Portfolio; Will Augment Already Strong Growth Prospects
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Jan 2013
FDA Approves Fulyzaq(TM) (Crofelemer) 125 mg Delayed-Release Tablets for the Symptomatic Relief of Diarrhea in Patients with HIV/AIDS on Anti-Retroviral Therapy (ART)
Biopharmaceuticals FDA HIV/AIDS
 HSMN NewsFeed - 30 Aug 2011
Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR(R) in Patients with Non-Cancer Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jun 2010
Salix Pharmaceuticals Announces NDA Submission For XIFAXAN550 For Treatment of Non-Constipation Irritable Bowel Syndrome
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 24 Mar 2010
FDA Approves XIFAXAN(R) 550 MG Tablets for Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence
Biopharmaceuticals FDA
 HSMN NewsFeed - 23 Feb 2010
FDA Advisory Committee Recommends Approval Of XIFAXAN(R) (rifaximin) Tablets, 550 Mg for Maintenance of Remission of Hepatic Encephalopathy
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Feb 2010
Medivir partners with Meda to commercialize Xerese(TM) (Lipsovir(R)) in North America
Biopharmaceuticals
 HSMN NewsFeed - 8 Sep 2009
Salix Receives FDA Marketing Approval for METOZOLV ODT (Orally Disintegrating Tablets) for Relief of Diabetic Gastroparesis and Symptomatic Documented GERD
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 1 Jun 2009
Positive Results from Salix Pivotal Phase III Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE) Presented at Digestive Disease Week (DDW)
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Apr 2009
Salix Presents Highly Statistically Significant Results from the Phase III Pivotal Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE)
Biopharmaceuticals
 HSMN NewsFeed - 29 Dec 2008
Salix Receives FDA Complete Response Letter for Balsalazide Tablet
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 6 Nov 2008
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Nov 2008
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children
Biopharmaceuticals Endocrinology FDA
 HSMN NewsFeed - 3 Nov 2008
APRISO(TM) Granted FDA Marketing Approval for Maintenance of Remission of Ulcerative Colitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Oct 2008
Rifaximin Demonstrates Highly Statistically Significant Results in Prevention of Hepatic Encephalopathy in Pivotal Phase 3 Study
Biopharmaceuticals
 HSMN NewsFeed - 28 Jul 2008
Barrier Therapeutics Introduces Dual-Component Xolegel CorePak(TM) for Seborrheic Dermatitis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 7 Jul 2008
Xclair(R) Reported to Be Safe and Effective in Study Published in European Journal of Dermatology
Biopharmaceuticals Dermatology Oncology
 HSMN NewsFeed - 26 Feb 2008
CollaGenex Pharmaceuticals Signs Merger Agreement with Galderma Pharma S.A.
Biopharmaceuticals Dermatology Mergers & Acquisitions
 HSMN NewsFeed - 26 Feb 2008
Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
Biopharmaceuticals Dermatology Mergers & Acquisitions
 HSMN NewsFeed - 6 Feb 2008
Salix Announces Appointment of Mark Sirgo to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Dec 2007
Salix Pharmaceuticals Announces Submission of Granulated Mesalamine New Drug Application
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 4 Oct 2007
Salix Announces Statistically Significant Top- Line Results for Second Product Registration Study of Granulated Mesalamine in Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 4 Oct 2007
Salix Pharmaceuticals Licenses OSMOPREP(TM) To Mayoly-Spindler in France
Biopharmaceuticals Licensing Gastroenterology
 HSMN NewsFeed - 5 Sep 2007
Salix Pharmaceuticals Acquires Patent-Protected Metoclopramide-Zydis(R)
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Sep 2007
Salix Pharmaceuticals Announces Co-Promotion Agreement for Balsalazide
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Sep 2007
Rifaximin Demonstrates Statistically Significant Improvement in Co-Primary Endpoints in Treatment of Diarrhea-Associated Irritable Bowel Syndrome in Phase IIb Study
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 25 Jul 2007
A.T.S. Pharmaceuticals, A division of Auriga Laboratories Launches Xyralid(TM) LP Lotion
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 18 Jun 2007
Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 15 Jun 2007
Bradley Pharmaceuticals Launches Peranex(TM) HC Cream
Biopharmaceuticals
 HSMN NewsFeed - 8 Jun 2007
Salix Pharmaceuticals Announces Imminent Launch of Visiclear(R) in Japan
Biopharmaceuticals
 HSMN NewsFeed - 16 May 2007
CollaGenex Pharmaceuticals and QuatRx Pharmaceuticals Announce Agreement for the Development and Commercialization of Becocalcidiol
Biopharmaceuticals Dermatology Licensing
 HSMN NewsFeed - 7 May 2007
CollaGenex Pharmaceuticals Discontinues 40 mg Cohort of Phase II Dose-Finding Study of Incyclinide for the Treatment of Acne
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 2 May 2007
Paladin Acquires Products from Shire
Biopharmaceuticals Dermatology Acquisitions
 HSMN NewsFeed - 2 May 2007
CollaGenex Pharmaceuticals Provides Update on 40 mg Cohort of Phase II Dose-Finding Study of Incyclinide for the Treatment of Acne
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 30 Apr 2007
Evaluating the Efficacy and Safety of Once-Daily Anti-Inflammatory Dose Doxycycline for the Treatment of Rosacea
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 23 Apr 2007
CollaGenex Pharmaceuticals Provides Update on Examination of Incyclinide Patent Application
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 2 Feb 2007
Positive Results of Phase 4 Clinical Study Evaluating Effects of Oracea(TM) (doxycycline, USP) Capsules, 40 mg, in Combination with MetroGel(R) (metronidazole gel), 1%, as Treatment for Rosacea Presented at Annual Meeting of the AAD
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 20 Dec 2006
CollaGenex Pharmaceuticals Signs License and Supply Agreement with MediGene for Marketing Rights to Oracea in EU and Certain Other Countries
Biopharmaceuticals Dermatology Licensing
 HSMN NewsFeed - 5 Dec 2006
CutisPharma Completes Progesterone Vaginal Suppository Product Line
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 23 Oct 2006
Salix Pharmaceuticals Reports American College of Gastroenterology Update
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 26 Sep 2006
CutisPharma Launches 25 mg Strength in Progesterone Vaginal Suppository Product Line
Biopharmaceuticals
 HSMN NewsFeed - 30 May 2006
CollaGenex Pharmaceuticals Receives FDA Approval for Oracea(TM)
Biopharmaceuticals Dermatology FDA
Return to NewsFeed  

 Additional items found! 22

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 22 additional stories matching:
hydrocortisone
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.